An observational study in Solid Tumor, sponsored by National Cancer Centre, Singapore. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by National Cancer Centre, Singapore · Observational
This observational study aims to assess the outcomes in patients with advanced treatment refractory cancers with matched molecular/precision therapy as per their molecular profiling results after discussion at molecular tumour board.
To standardize response assessment and data collection for patients that are receiving off-label or non-standard therapies based on MTB recommendations.
- Establish a standardized response assessment process and data collection patients that are receiving off-label or non-standard therapies based on MTB recommendations.
To demonstrate that it is feasible to standardize investigations and endpoints in this proof-of-concept study.
Hypothesis: Our proposed IMPACT-INSPIRE study hypothesis is that standardised response assessment and data collection in patients with no available therapies receiving off-label systemic therapies, can provide a novel mechanism to assess oncological outcomes in this unique cohort of patients, generate hypothesis, and provide insights to future biomarker-driven drug development
The patient will be observed clinically after informed consent has been obtained. Patients may require more frequent assessment or additional procedures as clinically necessary or as required by the product label.
National Cancer Centre, Singapore is the lead sponsor of 116 studies on the registry; 30 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Histologic or cytologic confirmation confirmed of advanced refractory solid tumours with no further suitable treatment options.
Exclusion Criteria:
Histologic or cytologic confirmed advanced treatment refractory solid tumours with no further suitable standard treatment options.
Other: Off-label or non-standard systemic therapies
Off-label systemic treatments and/or relevant clinical trials recommended by the NCCS Molecular Tumour Board (MTB).
Best objective response rate at 12 weeks
The percentage of participants with best overall response of complete response (CR) or partial response (PR).
Time frame: Up to 12 weeks.
Tumour growth rate inhibition
Duration that patient is on experimental therapy as a fraction of the total duration on last line of therapy.
Time frame: Up to 12 weeks.
Incidence of adverse events (AEs), Identified and graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 criteria.
Time frame: From the initiation of protocol therapy, up to 30 days after last dose of off-label or non-standard therapy.
Quality of life thorough AE evaluation or equivalent instruments such as the EORTC QLQ-C30 questionnaire.
Time frame: Baseline and after every 2 cycles till end of treatment, up to 2 years.
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cancer Centre, Singapore